

**7-5/2016/EU/WC-0363**  
**Government of India**  
**Directorate General of Health Services**  
**Central Drugs Standard Control Organisation**  
**(International Cell)**

FDA Bhawan, Kotla Road,  
New Delhi-110002

**Dated:**

To

**M/s. Centrient Pharmaceuticals India Pvt. Ltd.,**  
**Bhai Mohan Singh Nagar, Toansa**  
**Dist. SBS Nagar (Nawanshahr)**  
**Punjab-144 533, India**

29 APR 2022

**Subject:- Written Confirmation of M/s. Centrient Pharmaceuticals India Pvt. Ltd., Bhai Mohan Singh Nagar, Toansa Dist. SBS Nagar (Nawanshahr) Punjab-144 533, India as per requirement of EU for import of active substances imported into the European Union (EU) for medicinal products for human use, in accordance with Article 46b(2)(b) of Directive 2001/83/EC from India-Reg.**

Sir,

Please refer to your online application no. WC/RE/2022/1704 submitted to CDSCO, Sub-Zone office Baddi and the recommendation received from ADC (I), Sub-Zone office Baddi on the above noted subject

Written Confirmation as required for active substances imported into the European Union (EU) for medicinal products for human use, in accordance with Article 46b(2)(b) of Directive 2001/83/EC from India is herewith granted subject to the following conditions:-

1. The Active Pharmaceutical Ingredients shall conform to Good Manufacturing Practices mentioned in the EU directives or other equivalent (GMP of WHO/ICH Q7).
2. The manufacturer is subject to regular, strict and transparent controls and to the effective enforcement of Good Manufacturing Practice, including repeated and unannounced inspections, so as to ensure a protection of public health equivalent to that in the EU.
3. The manufacturer is required to follow the Guidance document for Issue of Written Confirmation as issued by CDSCO.
4. Written Confirmation shall be produced by the Authorized Exporter as and when required by the Drug Regulatory Authority.
5. The Written Confirmation will be withdrawn in the events of non compliance of Standards.
6. This Written Confirmation, unless it is sooner suspended or cancelled, shall be valid for a period of three years.

7. In the event of any Non Compliance observed during inspections conducted by Local or International Drug Authorities, the same shall be forwarded to this office within 7 days of receipt of report.
8. In the event of any drug found not of standard quality, the same shall be reported to this office within 7 days of receipt of report.

Please note that Written Confirmation issued is liable to be suspended / cancelled, if any of the conditions stipulated above are not complied with or in case of violation of the provisions of the Drugs & Cosmetics Act, 1940 and the Rules thereunder as the case may be.

Please acknowledge the receipt.

Annexure No.	No. of Products	Date of Issue	Valid Upto
-	03	29 APR 2022	14.04.2025

s/c

Yours faithfully,

*Vhr*

(Dr. V.G.Somani)  
Drugs Controller General (India)

*Redundant*  
*29/04/2022*



Written confirmation for active substances imported into the European Union (EU) for medicinal products for human use, in accordance with Article 46b(2)(b) of Directive 2001/83/EC

1. Name and address of site: **M/s. Centrient Pharmaceuticals India Pvt. Ltd.,  
Bhai Mohan Singh Nagar, Toansa  
Dist. SBS Nagar (Nawanshahr)  
Punjab-144 533, India**

2. Manufacturer's licence number: 1879-OSP

Regarding the manufacturing plant under (1) of the following Active substance(s) exported to the EU for medicinal products for human use

**List of APIs below**

S. No.	Active substance(s)	Activity(ies)
1.	Atorvastatin Calcium IP/USP	Manufacturing & Packing
2.	Atorvastatin Calcium Trihydrate BP/Ph.Eur	Manufacturing & Packing
3.	Rosuvastatin Calcium IP/BP/EP/USP	Manufacturing & Packing

The issuing Regulatory Authority hereby confirms that:

The standards of good manufacturing practice applicable to this manufacturing plant are at least equivalent to those laid down in the EU (=GMP of WHO/ICH Q7);

The manufacturing plant is subject to regular, strict and transparent controls and to the effective enforcement of good manufacturing practice, including repeated and unannounced inspections, so as to ensure a protection of public health at least equivalent to that in the EU; and

In the event of findings relating to non-compliance, information on such findings is supplied by the exporting third country without delay to the EU.

*alc* Date of Inspection of the plant: 03.03.2022 & 04.03.2022

The Written Confirmation remains valid until: 14.04.2025

The authenticity of this written confirmation may be verified with the issuing regulatory authority.

This written confirmation is without prejudice to the responsibilities of the manufacturer to ensure the quality of the medicinal product in accordance with Directive 2001/83/EC.

**Address of the issuing regulatory authority: Central Drugs Standard Control Organisation**  
FDA Bhawan, Kotla Road,  
New Delhi- 110 002, India

**Name and function of responsible person:** Dr. V.G Somani  
Drugs Controller General (India)

**E-mail:**

**Telephone no.:**

**Fax no.:**

dci@nic.in,  
+91-11-23236965  
+91-11-23236963

Signature *VL*

Stamp of the authority and date



29 APR 2022